Table 2.

Expression of IL-3Rα and β chains on primary malignant cells from patients suffering from BPDCN, acute myeloid leukemia (AML) cells, acute lymphoid leukemia (ALL) cells and cell lines −as assessed by mean fluorescence intensity − was compared with the viability after treatment with SL-401.

Table 2.